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Hepatitis C virus (HCV) infection induces several changes in hepatocytes,  such as oxidative stress,  
steatosis,  and hepatocarcinogenesis.  Although considerable progress has been made during recent 
years,  the mechanisms underlying these functions remain unclear.  We employed proteomic techniques 
in HCV replicon-harboring cells to determine the eﬀects of HCV replication on host-cell protein expres-
sion.  We examined two-dimensional electrophoresis (2-DE) and mass spectrometry to compare and 
identify diﬀerentially expressed proteins between HCV subgenomic replicon-harboring cells and their 
“cured” cells.  One of the identiﬁed proteins was conﬁrmed using enzyme-linked immunosorbent assay 
(ELISA) and Western blot analysis.  Full-length HCV genome RNA replicating and cured cells were also 
assessed using ELISA.  Replicon-harboring cells showed higher expression of retinal dehydrogenase 1 
(RALDH-1),  which converts retinol to retinoic acid,  and the cured cells showed higher expression of 
retinol-binding protein (RBP),  which transports retinol from the liver to target tissues.  The alteration 
in RBP expression was also conﬁrmed by ELISA and Western blot analysis.  We conclude that protein 
expression proﬁling demonstrated that HCV replicon eradication aﬀected retinol-related protein 
expression.
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epatitis C virus (HCV) is the most common 
hepatitis virus in Japan.  Approximately 85ｵ of 
cases progress to chronic infection,  resulting in liver 
cirrhosis and hepatocellular carcinoma.  HCV is a 
member of the Flaviviridae family and possesses a 
single-stranded,  sense RNA genome of about 9.6kb 
that encodes a single polyprotein.  This precursor 
protein is cleaved co- and post-transcriptionally into at 
least 10 proteins: core,  envelope (E) 1,  E2,  p7,  
nonstructural protein (NS) 2,  NS3,  NS4A,  NS4B,  
NS5A,  and NS5B [1,  2].  Although many studies 
have examined the functions of single proteins,  the 
function of the polyprotein has not been suﬃciently 
studied,  owing to the lack of reproducible HCV pro-
liferation in cell culture systems.
　 Recent advances in cell culture have enabled the 
reproducible implementation of the HCV replication 
system.  An HCV replicon system that contained HCV 
nonstructural proteins and showed autologous replica-
tion of the HCV proteins was ﬁrst established in 
H
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1999 [3].  Recently,  a full-length HCV genome con-
taining replication system was introduced,  followed by 
an in vitro viral replication system that can produce 
HCV viral particles,  has also been established [4-8].
　 Recent advances in genomic and proteomic tech-
nologies have provided powerful tools for studying the 
global characteristics of host cell protein responses to 
HCV in vitro.  Reﬁned multidimensional liquid chro-
matographic (LC) separation,  coupled with mass 
spectrometry (MS) for proteome analysis,  has enabled 
global analysis using less protein and with increased 
sensitivity,  throughput,  and dynamic range than with 
previous proteomic techniques.  Although the eﬃcient 
replication of an HCV subgenomic replicon is thought 
to aﬀect the gene expression proﬁles of host cells [9,  
10],  few proteomic analyses of this system have been 
reported [11].
　 In the present study,  a proteomic approach was 
utilized to compare global protein expression proﬁles 
in HCV subgenomic replicon-harboring cells with 
“cured” cells,  from which the replicons had been 
eliminated by prolonged treatment with interferon 
(IFN) alpha.
Materials and Methods
　 Cell cultures. The sO cells,  harboring HCV 
subgenomic replicons derived from genotype 1b 
strains,  were produced from HuH-7 cells [12].  
sAH1 cells harboring the HCV subgenomic replicons 
were used to establish a cloned cell line,  using an 
HCV replicon RNA library constructed with the HCV 
AH1 strain [7].  AH1 cells,  harboring HCV full 
genome RNA were established from a full-length HCV 
genome RNA by the transfection of HCV RNA into 
sAH1c cells.  sAH1c cells were “cured sAH1 cells” 
which were created by eliminating HCV RNA from 
transfected subgenomic replicon-harboring sAH1 cells 
by prolonged IFN alpha treatment.  Cured cells were 
used because these enhanced the colony formation of 
the subgenomic replicon more than did parental HuH-7 
cells [8].  
　 The sO and sAH1 cells were maintained in 
Dulbeccoｾs modiﬁed Eagleʼs medium (DMEM) supple-
mented with 10ｵ fetal bovine serum and G418 
(300µg/ml; Geneticine,  Invitrogen,  Carlsbad,  CA,  
USA).  HCV RNA-replicating cells are G418-
resistant due to the production of neomycin phospho-
transferase (NeoR) from the eﬃcient replication of 
HCV RNA.  The presence of G418 is toxic when HCV 
RNA is excluded from the cells or its levels are 
decreased.  Therefore,  cured cells obtained from sO 
and sAH1 cells were maintained in the absence of 
G418.
　 IFN treatment (establishment of cured cells).
The sO and sAH1 cells are sensitive to IFN [7,  12].  
To prepare cured cells,  sO and sAH1 cells (1×106) 
were plated onto 10-cm plates and cultured for 1 day 
immediately prior to IFN treatment.  Human IFN 
alpha (Sigma,  St.  Louis,  MO,  USA) was added to 
the cells at a ﬁnal concentration of 3,000IU/ml.  The 
cells were incubated in the absence of G418 for 3 
weeks with the addition of IFN alpha (3,000IU/ml) at 
4-day intervals.  The cured cells obtained from sO and 
sAH1 cells were named sOc and sAH1c,  respectively.  
Negativity for HCV-RNA was conﬁrmed by RT-PCR 
and deﬁned as “cured” cells.
　 Protein extraction and two-dimensional elec-
trophoresis (2-DE). Cells were washed with 
phosphate-buﬀered saline (PBS),  and harvested by 
mechanical scraping during the exponential growth 
phase.  Cells were centrifuged,  and the cell pellets 
were dissolved in lysis buﬀer consisting of 5M urea,  
2M thiourea,  2ｵ 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propane sulfonate (CHAPS),  
2ｵ sulfobetaine (SB) 3-10,  1ｵ dithiothreitol (DTT) 
and a protease inhibitor cocktail (Sigma-Aldrich,  St.  
Louis,  MO,  USA).  After three freeze-thaw cycles,  
the pellets were sonicated for 30 sec and ultracentri-
fuged at 75,000g for 30min at 10℃ using an OptimaTM 
TLF Ultracentrifuge (Beckman Coulter,  Brea,  CA,  
USA).  The supernatant was transferred to a new tube 
and treated with a ReadyPrep 2D Cleanup Kit (Bio-
Rad,  Hercules,  CA,  USA) to remove ions,  DNA,  and 
RNA.  The protein concentration was estimated using 
an RC-DC Protein Assay (Bio-Rad),  according to a 
standard two-washed protocol.  Pharmalyte 3-10 for 
isoelectric focusing (IEF) was formulated to increase 
the resolution at the basic end of a ﬂatbed isoelectric 
focusing gel.
　 The ﬁrst dimension IEF was performed using a 
17-cm immobilized pH gradient (IPG) DryStrip (Bio-
Rad),  nonlinear pH 3-10.  After rehydration for 15h 
in 300µL buﬀer consisting of 5M urea,  2M thiourea,  
2ｵ CHAPS,  3ｵ SB3-10,  1ｵ DTT,  and 0.2ｵ 
Bio-Lyte® 3/10 ampholyte (Bio-Rad),  the protein 
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samples,  60µg each,  were loaded onto the strips.  
Focusing was accomplished with the following condi-
tions: 250V for 40min,  10,000V for 4h,  a third step 
with a total 70,000V-h,  and ﬁnally maintenance at 
500V as needed.
　 The focused strips were then equilibrated in buﬀer 
I (6M urea,  2ｵ sodium dodecyl sulfate (SDS),  
0.375M Tris-HCl pH8.8,  20ｵ glycerol,  2ｵ DTT) 
for 30min and then in buﬀer II (6M urea,  2ｵ SDS,  
0.375M Tris-HCl pH8.8,  20ｵ glycerol,  2.5ｵ iodo-
acetamide) for 15min with gentle shaking.  The sec-
ond-dimension separation was carried out on 12ｵ 
SDS-polyacrylamide gels using PROTEAN II Cell 
(Bio-Rad) at 20℃ using 40mA/gel constant amps for 
4h.  After 2-DE,  the gels were stained with SYPRO 
Ruby (Invitrogen) according to the manufacturerʼs 
protocol.
　 Image analysis of 2-DE gels. Images of 
SYPRO Ruby-stained gels were obtained using an 
FLA-3000 (Fujiﬁlm,  Tokyo,  Japan) image analyzer.  
Background subtraction,  spot detection,  and volume 
normalization were performed with PDQuest Advanced 
Version 8.0 software (Bio-Rad).  The gels were then 
destained and restained with a silver staining kit 
(Dodeca Silver Stain kit,  Bio-Rad).  The spot inten-
sity of each sample was determined and analyzed with 
PDQuest Advanced Version 8.0 software (Bio-Rad).  
The intensities of the matched spots were compared,  
and diﬀerences＞1.5-fold were conﬁrmed by visual 
inspection.  Three independent experiments were 
performed.
　 Protein identiﬁcation using mass spectrom-
etry. Overexpressed protein spots were selected 
based on Sypro Ruby staining intensity.  Spots of 
interest were manually excised after silver staining.  
Gel spots were washed and digested with sequencing-
grade trypsin and the resulting peptides were 
extracted using standard protocols.  Peptide sequenc-
ing was accomplished by using a nanoﬂow HPLC,  with 
electronic ﬂow control (1100 Series nanoﬂow LC 
system,  Agilent Technologies,  Palo Alto,  CA,  USA),  
interfaced to an ion trap mass spectrometer 
(LC-MSD Trap SL,  Agilent Technologies).  A 
reverse-phase column (75mm×150mm,  C18 Zorbax 
StableBond) was used as the analytical column.  The 
MS data were searched against a subset of human 
proteins in the Spectrum Mill for MassHunter 
Workstation software,  protein sequence database.  
Positive protein identiﬁcation was based on a total 
MS/MS search score of＞21.
　 Analysis of retinol-binding protein (RBP) 
levels using ELISA. Conditioned medium was 
collected from sO and sOc cells.  Cell extracts were 
prepared by treatment with cell lysis buﬀer (MBL,  
Nagoya,  Japan) and centrifuged at 15,000rpm for 5 
min.  Protein concentrations were determined by the 
colorimetric BioRad protein assay.  The protein con-
centrations in the sO cells and sOc samples were 
equalized.  RBP concentrations in culture superna-
tants were measured by an RBP ELISA kit 
(Assaypro,  St.  Charles,  MO,  USA) according to the 
manufacturerʼs instructions.
　 Analysis of RBP levels using Western blot 
analysis. Cultured cells were washed twice with 
ice-cold PBS and lysed with lysis buﬀer (0.1M Tris-
HCl,  4ｵ SDS,  10ｵ glycerol,  0.004ｵ bromophenol 
blue,  10ｵ 2-mercaptoethanol).  The lysates were 
collected and boiled for 5min.  Samples were electro-
phoresed on a 15ｵ SDS-polyacrylamide gel,  and 
transferred to a PVDF transfer membrane (Millipore,  
Bedford,  MA,  USA).  Membranes were blocked in 
5ｵ BSA in 20mM Tris-HCl (pH7.6),  137mM NaCl,  
and 0.1ｵ Tween 20 (TBS-T) for 1h at 37℃,  and 
then probed at 4℃ overnight with antibodies in 
TBS-T containing 1ｵ BSA.  The primary antibodies 
were rabbit anti-beta actin (Sigma) and goat anti-RBP 
(Abcam,  Cambridge,  MA,  USA).  After washing,  the 
membranes were incubated with a peroxidase-conju-
gated secondary antibody (anti-rabbit: Amersham 
Biosciences,  Piscataway,  NJ,  USA) (anti-goat: R&D 
Systems,  Minneapolis,  MN,  USA) at room tempera-
ture for 1h,  and visualized with an enhanced chemilu-
minescence detection system (Amersham Biosciences).
　 Analysis of RBP and retinal dehydrogenase 
1 (RALDH-1) mRNA expression by reverse 
transcription polymerase chain reaction 
(RT-PCR). Expression levels of RBP and 
RALDH-1 genes were analyzed using RT-PCR.  
Total RNA was extracted from cell lines by using 
TRIzol reagent (Life Technologies,  Carlsbad,  CA,  
USA).  Two micrograms of total RNA was reverse-
transcribed into cDNA using ReverTra Ace (Toyobo,  
Osaka,  Japan) at 42℃ for 20min followed by 99℃ 
for 5min using oligo (dT) primer according to the 
manufacturerʼs instructions.  The resulting cDNA was 
subjected to PCR using the following primers (for-
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ward PCR and reverse PCR primers,  respectively):
RBP ( F: 5ʼ-TTCCGAGTCAAAGAGAACTTCG 
R: 5ʼ-TCATAGTCCGTGTCGATGATCC)
RALDH-1 ( F: 5ʼ-TACTCACCGATTTGAAGATT 
R: 5ʼ-TTGTCAACATCCTCCTTATC)
GAPDH ( F: 5ʼ-CACCCACTCCTCCACCTTTG 
R: 5ʼ-GTCCACCACCCTGTTGCTGT)
　 PCR reactions were performed using the KOD 
Dash DNA polymerase (Toyobo).  PCR temperature 
conditions for RBP ampliﬁcation were as follows: 30 
cycles at 94℃ for 30sec,  60℃ for 2sec,  and 74℃ 
for 30sec.  PCR temperature conditions for RALDH-1 
ampliﬁcation were as follows: 35 cycles at 94℃ for 
30 sec,  51℃ for 2 sec,  and 72℃ for 30 sec.  To 
deﬁne the best ampliﬁcation conditions for these 
genes,  we tried 25,  30,  35,  and 40 cycles of PCR.  
We found that 30 cycles for RBP and 35 cycles for 
RALDH-1 were the best conditions.  For each primer 
set,  the sense and antisense primer pairs were located 
on diﬀerent exons to avoid ampliﬁcation of contami-
nating genomic DNA.  The housekeeping gene GAPDH 
(with the following ampliﬁcations: 30 cycles of 94℃ 
for 30 sec,  61℃ for 2 sec,  and 72℃ for 30 sec) was 
used as an internal control to conﬁrm the success of 
the RT-PCR.  PCR products were analyzed on 2ｵ 
agarose gels stained with ethidium bromide.
　 Statistical analysis. Results were expressed 
as means±standard deviation (SD).  All data were 
compared using Studentʼs t test (Stat View,  Cary,  
NC,  USA).  Data were considered statistically sig-
niﬁcant at p＜0.05.
Results
　 Proteomic proﬁling analysis of sO and sOc 
cells. Fig.  1 shows representative images of pro-
teomic proﬁling of sO and sOc cells.  Five spots were 
identiﬁed as reduced in sOc (spots: 1 to 5) and 3 spots 
were identiﬁed as enhanced in sOc (spots: 6 to 8) 
(Fig.  1).
　 Protein identiﬁcation of detected spots.
The results of LC/MS analysis are shown in Table 1.  
Ubiquitin carboxyl-terminal hydrolase isozyme L1 
(UCH-L1),  hemoglobin beta subunit,  T-complex 
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Fig.  1　 2-DE analyses of proteins extracted from sO and sOc cells.  Total protein extracts from the sO and sOc cells were separated on 
nonlinear IPG strips (pH3-10) in the ﬁrst dimension followed by 12% SDS-PAGE in the second dimension,  and then were visualized by 
SYPRO Ruby staining.  The boxed areas were identical between sO and sOc.
protein 1 subunit gamma (TCP1-gamma),  RALDH-1,  
and Elongation factor 2 were down-regulated in sOc 
cells,  i.e.,  interferon-induced or HCV elimination-
induced.  UCH-L1 was divided into 2 spots that might 
be modiﬁed.  Conversely,  myosin light polypeptide 6,  
Rho GDP-dissociation inhibitor 1 (Rho-GDI alpha),  
and the plasma retinol-binding protein (RBP) precur-
sor were upregulated in sOc cells.
　 Of these proteins,  retinol metabolism-related pro-
teins were included in both downregulated (RALDH-
1) and upregulated (RBP) by HCV eradication.  Thus,  
we further examined the expression of these proteins.
　 RBP and RALDH-1 mRNA expression.
We examined the expression levels of RBP and 
RALDH-1 in sO and sOc cells by RT-PCR in order 
to explore retinolʼs role in HCV replicon-harboring 
cells.  No signiﬁcant diﬀerences in RBP and RALDH-1 
mRNA expression were found between sO and sOc cell 
lines (Fig.  2A).
　 RBP expression. Western blot analysis and 
ELISA were employed for RBP analysis.  The 
Western blot results,  shown in Fig.  2B,  indicate that 
RBP expression was higher in sOc cells than in sO 
cells.  The ELISA results,  shown in Fig.  2C,  indi-
cated that the RBP level in sOc cells was signiﬁ-
cantly (1.6times) higher than that in sO cells (p＜
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Table 1　
A) Proteins upregulated in sO
1　Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1)
2　Hemoglobin subunit beta
3　T-complex protein 1 subunit gamma (TCP1-gamma)
4　Retinal dehydrogenase 1 (RALDH-1)
5　Elongation factor 2
B) Proteins upregulated in sOc
6　Myosin Light Polypeptide 6
7　Rho GDP-dissociation inhibitor 1
8　Plasma retinol binding protein
A RBP and RALDH1 mRNA expression
RBP
RALDH
GAPDH
311bp
151bp
112bp
sO sOc
B RBP : Western blotting
RBP
beta actin
21kDa
45kDa
sO sOc
C RBP : ELISA
sO sOc
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Fig.  2　 (A) RT-PCR analysis of RBP and RALDH-1 in sO and sOc cells.  The expression of GAPDH was used as an internal control.  
(B) Western blot analysis of RBP in sO and sOc cells.  Actin was used as a loading control.  (C) Analysis of RBP levels by ELISA in sO 
and sOc cells.  The results are expressed as fold increases compared to sO cells.  The data represent mean±SD of triplicate measure-
ments.  ＊p＜0.01
0.01).
　 Additionally,  we employed ELISA to compare 
RBP levels in sAH1 and sAH1c cells.  RBP expres-
sion levels did not diﬀer between sAH1 and sAH1c 
cells (Fig.  3).
Discussion
　 We have shown that,  compared with cured cells,  
HCV subgenomic replicon-harboring cells bear more 
Hemoglobin subunit beta,  TCP1-gamma,  RALDH-1,  
Elongation factor 2,  and UCH-L1.  Furthermore,  
when the replicon-harboring cells were treated with 
interferon,  thereby eliminating HCV proteins,  myosin 
light polypeptide 6,  Rho GDP-dissociation inhibitor 1 
(Rho-GDI alpha),  and plasma RBP precursor were 
upregulated.
　 Since these proteins have many functions and do not 
belong to a single functional category,  we concen-
trated our next step on retinol-related proteins RBP 
and RALDH-1,  which HCV elimination both upregu-
lated and downregulated.
　 Other molecules were used as follows,  and we did 
not subject them to further analysis.  UCH-L1 is a 
member of a group of deubiquitinating enzymes and is 
one of the most abundant proteins in the brain [13].  
It has been linked to Parkinsonʼs disease,  neuronal 
degeneration,  and neuropathic pain.  Additional evi-
dence implicates it in other organ cancers.  UCH-L1 
is expressed in certain lung cancer cell lines and in 
breast cancer cells,  especially in high grade tumors 
[14,  15].  Hemoglobin (Hb) is a heterotetramer,  con-
sisting of 2α-chain and 2β-chain subunits that form 2 
semirigid αβ dimers (α1β1 and α2β2).  Hemoglobin beta 
is a hemoglobin subunit.  TCP1-gamma is a member of 
the group II chaperonin family.  The substrates for 
TCP1-gamma are cytoskeletal proteins such as tubu-
lins,  actins,  and cyclin E.  It is also thought to be 
involved in cell growth,  since TCP1-gamma is strongly 
upregulated during the G1/S phase transition of the 
cell cycle through the early S phase [16].  Disruption 
of the TCP1-gamma function using siRNA results in 
the inhibition of cell proliferation,  decreased cell 
viability,  cell-cycle arrest,  and cellular apoptosis [17].  
Elongation factor 2 is known to regulate protein syn-
thesis.  Elongation factor 2 catalyzes the ribosomal 
translocation reaction,  resulting in movement of ribo-
somes along mRNA during protein translation,  
thereby increasing protein synthesis.  Elongation fac-
tor 2 also has anti-apoptotic eﬀects against TNF-
alpha or HIV-1 viral protein R-induced apoptosis 
[18].  
　 The non-structural HCV proteins in our replicon-
harboring cells may increase retinoic acid as a result 
of RALDH-1 upregulation.
　 In our proteomic proﬁling analysis of sO and sOc 
cells,  2 proteins involved in retinol (vitamin A) 
metabolism were markedly altered.  The liver is the 
major site of vitamin A-loaded RBP production for the 
purpose of vitamin A delivery to peripheral organs.  
Eradication of the HCV replicon resulted in RALDH-1 
downregulation and RBP upregulation.
　 Dietary retinol is absorbed in the intestine,  pro-
cessed into retinyl esters,  and transferred into the 
circulation.  The circulating retinyl esters are taken to 
the liver and converted to retinol.  A portion of the 
hepatic retinol is bound to a cellular binding protein 
(CRBP) and stored.  The remainder of the hepatic 
retinol is bound to RBP and transported to target 
cells.  Retinol is oxidized to retinal by a subfamily of 
alcohol dehydrogenase (ADH) enzymes.  Retinal is 
oxidized to retinoic acid (RA) by 3 retinaldehyde 
dehydrogenases (RALDHs): RALDH-1,  RALDH-2,  
and RALDH-3.  These enzymes are expressed in dif-
ferent patterns and play speciﬁc roles in various tis-
sues [19].  RA has many functions and can modulate a 
variety of important processes,  such as cell growth 
and diﬀerentiation,  the induction of apoptosis,  and the 
prevention of angiogenesis.  All-trans- and 9-cis-
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Fig.  3　 RBP levels as determined by ELISA in sAH1 and sAH1c 
cells.  The results are expressed as fold increases compared to 
sAH1 cells.  The data represent mean±SD of triplicate measure-
ments.  ＊p＝0.53
retinoic acid regulate transcription and target gene 
expression through binding to the retinoic acid recep-
tor (RAR) and the retinoid X receptor (RXR),  within 
the nucleus.
　 Retinol is stored in hepatic stellate cells as retinyl 
ester and secreted into the blood bound to RBP,  
which is synthesized mainly in the liver [20].  
Therefore,  the concentration of plasma vitamin A is 
strongly related to the synthesis of RBP in the liver.  
Moreover,  RBP synthesis depends on vitamin A levels 
in the hepatocyte,  and the levels of vitamin A and 
RBP are correlated.  RBP is eliminated by the kidney 
with a half-life of 12h in the circulation.
　 The parental HuH-7 cells may not be appropriate 
for use as control cells in proteomic analysis,  because 
the HCV subgenomic replicon cells used are derived 
from a single cloned cell.  Therefore,  it is very impor-
tant to avoid clone-based diﬀerences for the proteomic 
analysis.  From this point of view,  we compared HCV 
replicon-harboring cells and their cured cells.  In HCV 
replicon-harboring cells,  RALDH-1 was increased 
and might induce retinoic acid production.  When the 
HCV is eliminated,  the activation of retinol metabo-
lism is reduced and may result in an increase in retinol 
that could induce RBP precursor upregulation.  
Although RALDH-1 was increased,  proteins down-
stream from retinol metabolism,  such as retinoic acid 
or retinoic acid receptors,  were not upregulated in our 
experiment.  This might be explained by either 1) the 
eﬀects being minimal,  or 2) the downstream pathway 
being compromised.  In infection with another hepa-
totropic virus,  hepatitis B,  HBx protein is known to 
promote oncogenesis.  The HBx gene has been reported 
to induce promoter hypermethylation in the retinoic 
acid receptor β2 (RAR-β2) gene,  resulting in 
decreased susceptibility to retinoic acid-induced cell 
growth inhibition [21].  Both the hepatitis B and C 
viruses have pathologic eﬀects on the liver,  resulting 
in chronic hepatitis and hepatocarcinogenesis.  Retinol 
metabolism dysfunction could be involved in this com-
mon pathology.
　 In our experiment,  RBP expression in full-length 
HCV genome-containing sAH1 cells was not diﬀerent 
from that in cured cells,  whereas the subgenomic 
replicon-harboring sO cells containing non-structural 
proteins exhibited decreased RBP levels.  The HCV 
core protein has been reported to aﬀect retinol 
metabolism.  A comprehensive analysis of gene expres-
sion in the liver of core gene-expressing transgenic 
mice revealed the downregulation of RBP [22].  The 
HCV core protein is reported to bind Sp110b,  a 
transcriptional suppressor of retinoic acid receptor 
(RAR),  and to suppress the function of Sp110b,  
which results in the activation of retinoic acid-related 
functions,  such as apoptosis [23].  The core protein 
has been found to interact with RXRα in its DNA-
binding domain [24].  These results led us to under-
stand that the core protein and the non-structural 
proteins both decrease RBP.  However,  their co-
expression might interfere with these eﬀects.  Chronic 
infection with hepatitis C virus results in hepatocar-
cinogenesis 30 to 40 years post-infection.  This may 
illustrate that this virusʼs carcinogenic eﬀects are not 
strong enough to directly induce early cell prolifera-
tion.  Our present results indicate that the carcino-
genic eﬀect of individual HCV proteins may be con-
trolled by mutual interference.
　 Proteomic analysis of hepatitis B virus (HBV) 
replicon-harboring cells,  compared with parent cells,  
revealed that retinol metabolism-related proteins were 
diﬀerentially expressed [25].  In the HBV replicon-
harboring cells,  ALDH,  RBP and CRBP1 were up-
regulated.  Although the expression pattern was 
diﬀerent,  HBV,  another chronic hepatitis and hepato-
carcinogenic virus,  induced alterations in retinol 
metabolism-related proteins.  DNA microarray analy-
sis experiments comparing the same HCV subgenomic 
replicon cells (sO) with cured cells indicated that there 
was no eﬀect on retinol metabolism-related genes 
[26].  This illustrates that the HCV repliconʼs eﬀects 
on retinol metabolism-related proteins are post-tran-
scriptional.
　 In conclusion,  we have employed proteomic tech-
niques to elucidate the mechanisms underlying the 
replication and pathogenesis of HCV in HCV replicon-
harboring cells.  By comparing the protein expression 
proﬁles of HCV subgenomic replicon-harboring cell 
lines with cured cells,  we observed several alterations 
in proteins that are correlated with cell proliferation 
and apoptosis control,  including retinol metabolism.  
Such an analysis of the protein expression proﬁle in 
HCV replicon-harboring cells has extended our under-
standing of the mechanisms underlying HCV pathogen-
esis.
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